Tuesday, February 26, 2013
FDA Approves Phase III Study of Inlay for Presbyopia
ReVision Optics, Inc. (RVO), has received conditional approval from the U.S. Food and Drug Administration (FDA) to continue and complete enrollment in its Phase III clinical trial with its Raindrop™ Near Vision Inlay (formerly the PresbyLens). The prospective, multicenter Phase III clinical trial is evaluating the safety and effectiveness of the Raindrop Near Vision Inlay in improving near vision in subjects with presbyopia under an Investigational Device Exemption (IDE). Read more.